| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/12/2005 | US20050101664 Anionically coupling an acyl imidazoyl carbamate with a primary amide or carbamate; N-alkylation; inosine-5*-monophosphate dehydrogenase inhibitors |
| 05/12/2005 | US20050101662 Such as coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7- dihydroxycoumarin (exculetin), 3,6,7 trihydroxycoumarin, warfarin, or warfarin sodium; cancer, Alzheimer's disease, gout, atherosclerosis, restenosis |
| 05/12/2005 | US20050101657 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative |
| 05/12/2005 | US20050101653 Combination therapy for the treatment of migraine |
| 05/12/2005 | US20050101652 New salt hydrates |
| 05/12/2005 | US20050101651 Viricides; protease inbhibitors; useful for inhibiting the activity of picornaviral 3C proteases; for example, 6-carbamoyl-4S-{2S-[(5-naphthalen-1-yl-1H-pyrrole-2-carbonyl)-amino-3-phenyl-propionylamino}-hex-2(trans)-enoic acid ethyl ester |
| 05/12/2005 | US20050101649 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy |
| 05/12/2005 | US20050101647 For example, 2-(1,3-benzodioxol-5-yl)-6-phenyl-1H-imidazo[4,5-b]pyridinetyrosine; kinase-inhibiting activity; use in treatment of breast cancer, prostate cancer, lung cancer or pancreatic carcinoma |
| 05/12/2005 | US20050101641 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/12/2005 | US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases |
| 05/12/2005 | US20050101634 Bis(5-aeyl-2-pyridyl) derivatives |
| 05/12/2005 | US20050101633 spinal cord injury, spinal cord ischemia-reprefusion injury; P-sulfonamido- or carboxamido phenyl esters of pivalic acid; N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine monosodium salt tetrahydrate; elastase inhibitor; no side effects; inhibited accumulation and infiltration of neutrophil |
| 05/12/2005 | US20050101632 Treating inflammation of the skin or mucous membrane by topical administration of an anti-inflammatory amount of dimethicone in the absence of any other anti-inflammatory agent |
| 05/12/2005 | US20050101630 4-Anilino-, phenoxy-, or phenylthio-substituted; inhibitors of specific kinase enzymes, such as MEK enzymes |
| 05/12/2005 | US20050101625 Aerosol formulation for inhalation comprising an anticholinergic |
| 05/12/2005 | US20050101615 Pyridopyrimidine or naphthyridine derivative |
| 05/12/2005 | US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| 05/12/2005 | US20050101609 Quinazoline derivatives as kinase inhibitors |
| 05/12/2005 | US20050101600 4-Hydroxy-1-toluenesulfonyl-2,3,4,5-tetrahydro-1H-1-benzazepine, for example; useful as the preventive and/or treatment medicine against diseases caused by stress |
| 05/12/2005 | US20050101591 Fused bicyclic pyridine derivative as tachykinin receptor antagonist |
| 05/12/2005 | US20050101575 Vitamin d3 derivatives and remedies using the same |
| 05/12/2005 | US20050101573 Meiosis regulating compounds |
| 05/12/2005 | US20050101567 Using a sulfonamide containing compound |
| 05/12/2005 | US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders |
| 05/12/2005 | US20050101562 Lipase inhibiting composition |
| 05/12/2005 | US20050101557 Immunostimulatory nucleic acid molecules |
| 05/12/2005 | US20050101556 Genetic engineering; Alzheimer's disease; anticancer agents |
| 05/12/2005 | US20050101554 Methods for treating and preventing infectious disease |
| 05/12/2005 | US20050101524 Using arsenic oxide, or complex thereof; angiogenesis inhibitors; anticarcinogenic agents; neurodegenerative agents; antiischemic agents |
| 05/12/2005 | US20050101522 Antihyperplastic agents; antitumor agents; side effect reduction |
| 05/12/2005 | US20050101004 Screening for a compound to inhibit the urge for urinary incontinence by detecting activation of KCNQ protein in the host cell; measuring the membrane potential of the host cell and selecting the compound whose presence causes hyperpolarization in themembrane potential of the host cell |
| 05/12/2005 | US20050100918 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100917 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100913 RNA interference pathway genes as tools for targeted genetic interference |
| 05/12/2005 | US20050100902 5-cyano-1h-indole derivatives as antagonist of the inerleukine-8 receptors |
| 05/12/2005 | US20050100617 Method for improving age-related physiological deficits and increasing longevity |
| 05/12/2005 | US20050100607 administering polyethylene glycol or ethylene oxide-propylene oxide copolymers, with drugs, to improve delivery in the alimentary canal |
| 05/12/2005 | US20050100589 Transdermal administration of ace inhibitors |
| 05/12/2005 | US20050100547 Also a method for detecting an agent capable of binding TRAF2 binding site of sphingosine kinase by contacting cells with a putative agent and detecting an altered expression phenotype |
| 05/12/2005 | US20050100541 Ligands, including antibodies, showing reactivity against endocrine cells |
| 05/12/2005 | US20050100540 Platelet-activating factor acetylhydrolase |
| 05/12/2005 | US20050100530 Medicinal composition |
| 05/12/2005 | CA2544781A1 Plant-derived .beta.3-adrenergic receptor agonist substances and uses thereof |
| 05/12/2005 | CA2544425A1 Alpha-glucosidase activity inhibitor |
| 05/12/2005 | CA2540891A1 Use of extracts from the pelargonium species |
| 05/11/2005 | EP1529530A1 Compounds affecting glucokinase |
| 05/11/2005 | EP1529529A1 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for immunomodulation, immunostimulation and/or antiphlogistic treatment |
| 05/11/2005 | EP1529527A2 Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 05/11/2005 | EP1529062A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 05/11/2005 | EP1529058A2 A non-selective cation channel in neural cells and methods for treating brain swelling |
| 05/11/2005 | EP1529055A2 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof |
| 05/11/2005 | EP1529049A2 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 05/11/2005 | EP1529048A2 Methods for the synthesis of substituted purines |
| 05/11/2005 | EP1529046A1 Substituted benzimidazole compounds |
| 05/11/2005 | EP1529043A1 Novel process |
| 05/11/2005 | EP1529041A1 NOVEL PRODRUGS OF 1-METHYL-2(4-AMIDINOPHENYLAMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACID-( i N /i -2-PYRIDIL- i N /i -2-HYDROXYCARBONYLETHYL)-AMIDE, PRODUCTION AND USE THEREOF AS MEDICAMENTS |
| 05/11/2005 | EP1529038A1 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 05/11/2005 | EP1529030A2 Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid |
| 05/11/2005 | EP1528923A1 N-((3-oxo-2,3-dihydro-1h-isoindol-1-yl)acetyl)guanidine derivatives as nhe1-inhibitors for the treatment of infarction and angina pectoris |
| 05/11/2005 | EP1397363B1 5-ethyl-imidazotriazinones |
| 05/11/2005 | EP1363899B1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| 05/11/2005 | EP1309563B1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 05/11/2005 | EP1280531A4 Local anesthetic methods and kits |
| 05/11/2005 | EP1257526B1 Aniline-derived ligands for the thyroid receptor |
| 05/11/2005 | EP1254138B1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 05/11/2005 | EP1165541B1 Dimeric compounds and as inhibitors of neuraminidase |
| 05/11/2005 | EP1105738B1 Assays for modulating nuclear localisation |
| 05/11/2005 | EP1083931B1 Stabilization of compositions containing ace inhibitors using magnesium oxide |
| 05/11/2005 | EP1076563B1 Dipeptide caspase inhibitors and the use thereof |
| 05/11/2005 | EP1059930B1 Compositions comprising isovaleramide and ibuprofen |
| 05/11/2005 | EP1036092B1 Hydrophobically-modified hedgehog protein compositions and methods |
| 05/11/2005 | EP1005337B1 Pharmacologic drug combination in vagal-induced asystole |
| 05/11/2005 | EP0944725B1 Phosphodiesterase 8 |
| 05/11/2005 | EP0861071B1 Benzamidoxime prodrugs and use thereof for treating pneumonia |
| 05/11/2005 | EP0839196B1 Human ctla-8 and uses of ctla-8-related proteins |
| 05/11/2005 | CN1615439A Genes encoding g-protein coupled receptors and methods of use therefor |
| 05/11/2005 | CN1615307A Process and intermediates for pyridazinone antidiabetic agents |
| 05/11/2005 | CN1615306A C-5 modified indazolylpyrrolotriazines |
| 05/11/2005 | CN1615305A Coumarin derivatives, process for their production and use thereof |
| 05/11/2005 | CN1615300A Benzimidazole derivatives and their use as GNRH antagonists |
| 05/11/2005 | CN1615299A Xanthine oxidase inhibitors |
| 05/11/2005 | CN1615297A Phenoxy piperidines for treating diseases such as schizophrenia and depression |
| 05/11/2005 | CN1615157A Compositions inhibiting rejection in organ transplantation and method of using the same |
| 05/11/2005 | CN1615153A Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 05/11/2005 | CN1615152A Method for reducing acne or improving skin tone |
| 05/11/2005 | CN1615149A Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
| 05/11/2005 | CN1615148A Methods and compositions for derepression of IAP-inhibited caspase |
| 05/11/2005 | CN1615144A A composition for treating neurocerebrovascular disorders |
| 05/11/2005 | CN1615138A Melanogenesis inhibitors and whitening agents comprising ergosterol derivatives and compositions containing ergosterol derivatives |
| 05/11/2005 | CN1615137A Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 05/11/2005 | CN1615136A Combinations comprising epothilones and anti-metabolites |
| 05/11/2005 | CN1615135A Oral dosage form of a sulfonamide prodrug such as parecoxib |
| 05/11/2005 | CN1615134A Pharmaceutical compositions comprising valsartan and NEP inhibitors |
| 05/11/2005 | CN1615132A Melanogenesis inhibitors and whitening agents comprising egonol derivatives and compositions containing egonol derivatives |
| 05/11/2005 | CN1615131A Method for identification of tumor targeting enzymes |
| 05/11/2005 | CN1615128A Preparation for improving the action of receptors |
| 05/11/2005 | CN1615127A Substituted bicyclo[3.3.1]nonan-2, 4, 9-triones as pharmaceutical active ingredients |
| 05/11/2005 | CN1614003A Culture of Chansi mould strains and extraction and use of anagentic compound therefrom |
| 05/11/2005 | CN1613872A Interferon of IFN-beta-cn and its mutant |
| 05/11/2005 | CN1613482A Composition for improving memory and preparation thereof |